HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model.
Saved in:
| Title: | HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model. |
|---|---|
| Authors: | McCallion O; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Du W; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany., Glaser V; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Milward K; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Short S; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Bilici M; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Cross A; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Stark H; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Franke C; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany., Kath J; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA., Valkov M; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Yang M; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany., Amini L; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany., Künkele A; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Pediatric Hematology/Oncology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Berlin, Germany., Polansky JK; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany., Schmueck-Henneresse M; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany., Volk HD; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Reinke P; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Wagner DL; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. dimitrios-l.wagner@charite.de.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany. dimitrios-l.wagner@charite.de.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. dimitrios-l.wagner@charite.de.; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA. dimitrios-l.wagner@charite.de.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. dimitrios-l.wagner@charite.de.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. dimitrios-l.wagner@charite.de., Hester J; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. joanna.hester@nds.ox.ac.uk., Issa F; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. fadi.issa@nds.ox.ac.uk. |
| Source: | Nature communications [Nat Commun] 2025 Oct 13; Vol. 16 (1), pp. 9090. Date of Electronic Publication: 2025 Oct 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41083470 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22McCallion+O%22">McCallion O</searchLink>; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Du+W%22">Du W</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Glaser+V%22">Glaser V</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Milward+K%22">Milward K</searchLink>; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Short+S%22">Short S</searchLink>; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Bilici+M%22">Bilici M</searchLink>; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Cross+A%22">Cross A</searchLink>; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Stark+H%22">Stark H</searchLink>; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Franke+C%22">Franke C</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Kath+J%22">Kath J</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Valkov+M%22">Valkov M</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Yang+M%22">Yang M</searchLink>; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Amini+L%22">Amini L</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Künkele+A%22">Künkele A</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Pediatric Hematology/Oncology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Polansky+JK%22">Polansky JK</searchLink>; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Schmueck-Henneresse+M%22">Schmueck-Henneresse M</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Volk+HD%22">Volk HD</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Reinke+P%22">Reinke P</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Wagner+DL%22">Wagner DL</searchLink>; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. dimitrios-l.wagner@charite.de.; BIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany. dimitrios-l.wagner@charite.de.; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. dimitrios-l.wagner@charite.de.; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA. dimitrios-l.wagner@charite.de.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. dimitrios-l.wagner@charite.de.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. dimitrios-l.wagner@charite.de.<br /><searchLink fieldCode="AU" term="%22Hester+J%22">Hester J</searchLink>; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. joanna.hester@nds.ox.ac.uk.<br /><searchLink fieldCode="AU" term="%22Issa+F%22">Issa F</searchLink>; Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. fadi.issa@nds.ox.ac.uk. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2025 Oct 13; Vol. 16 (1), pp. 9090. <i>Date of Electronic Publication: </i>2025 Oct 13. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41083470 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41467-025-64945-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 9090 Titles: – TitleFull: HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: McCallion O – PersonEntity: Name: NameFull: Du W – PersonEntity: Name: NameFull: Glaser V – PersonEntity: Name: NameFull: Milward K – PersonEntity: Name: NameFull: Short S – PersonEntity: Name: NameFull: Bilici M – PersonEntity: Name: NameFull: Cross A – PersonEntity: Name: NameFull: Stark H – PersonEntity: Name: NameFull: Franke C – PersonEntity: Name: NameFull: Kath J – PersonEntity: Name: NameFull: Valkov M – PersonEntity: Name: NameFull: Yang M – PersonEntity: Name: NameFull: Amini L – PersonEntity: Name: NameFull: Künkele A – PersonEntity: Name: NameFull: Polansky JK – PersonEntity: Name: NameFull: Schmueck-Henneresse M – PersonEntity: Name: NameFull: Volk HD – PersonEntity: Name: NameFull: Reinke P – PersonEntity: Name: NameFull: Wagner DL – PersonEntity: Name: NameFull: Hester J – PersonEntity: Name: NameFull: Issa F IsPartOfRelationships: – BibEntity: Dates: – D: 13 M: 10 Text: 2025 Oct 13 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2041-1723 Numbering: – Type: volume Value: 16 – Type: issue Value: 1 Titles: – TitleFull: Nature communications Type: main |
| ResultId | 1 |
